Novavax
NVAX
#5815
Rank
NZ$1.87 B
Marketcap
NZ$11.52
Share price
-1.77%
Change (1 day)
-25.60%
Change (1 year)

P/S ratio for Novavax (NVAX)

P/S ratio as of December 2025 (TTM): 1.06

According to Novavax's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -6.91. At the end of 2025 the company had a P/S ratio of 1.36.

P/S ratio history for Novavax from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20251.36-30.27%
20241.94136.46%
20230.822231.11%
20220.6271-93.35%
20219.44-36.78%
202014.9116.33%
20196.90-66.56%
201820.638.17%
201714.9-32.93%
201622.3-64.37%
201562.535.26%
201446.2-9.57%
201351.1303.3%
201212.728.42%
20119.86-98.75%
2010787-4.14%
2009821567.88%
2008123-22.27%
2007158192.21%
200654.189.67%
200528.597.4%
200414.4-18.25%
200317.7286.66%
20024.57-66.51%
200113.6

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Agenus
AGEN
1.25 18.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.9625-8.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
0.8258-21.84%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
2.68 153.82%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
4.79 353.47%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
2.29 117.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
4.46 322.07%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
2.25 113.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
718 67,849.15%๐Ÿ‡บ๐Ÿ‡ธ USA